Vismodegib is under clinical development by Genentech USA and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vismodegib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vismodegib overview

Vismodegib (Erivedge) belongs to the class of anti-neoplastic agents. It is formulated as hard gelatin capsules for oral route of administration. Erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma (basal cell epithelioma) or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation and also for post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis and idiopathic pulmonary fibrosis,  for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy.

The drug candidate is under development for the treatment of Gorlin syndrome (basal cell nevus syndrome), refractory multiple myeloma, meningioma. It was also under development for relapsed and refractory acute myelogenous leukemia (AML), hepatocellular carcinoma, metastatic colorectal cancer (first-line therapy) and ovarian cancer, and idiopathic pulmonary fibrosis, relapsed/refractory high-risk myelodysplastic syndrome (MDS), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis, refractory or relapsed B-cell lymphoma or chronic lymphocytic leukemia, epithelial ovarian cancer, peritoneal cancer and fallopian tube cancer, keratocystic odontogenic tumors, menangiomas and neoadjuvant triple-negative breast cancer.

Genentech USA overview

Genentech USA (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. The company’s pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the treatment of non-small cell lung cancer; among others. The company has partnership with BioLineRx, Charles River Laboratories International, Amunix, among others. Genentech is headquartered in South San Francisco, California, the US.

For a complete picture of Vismodegib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.